Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Gains from Sales and Divestitures (2016 - 2024)

Historic Gains from Sales and Divestitures for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Q4 2024 value amounting to $1.9 million.

  • Ironwood Pharmaceuticals' Gains from Sales and Divestitures rose 1336.5% to $1.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.9 million, marking a year-over-year increase of 1336.5%. This contributed to the annual value of $1.9 million for FY2024, which is 1336.5% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Gains from Sales and Divestitures of $1.9 million as of Q4 2024, which was up 1336.5% from $1.7 million recorded in Q4 2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $1.9 million in Q4 2024 and a low of $965625.0 during Q4 2020
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $1.7 million (2023), whereas its average is $1.5 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Gains from Sales and Divestitures plummeted by 2563.74% in 2020 and then skyrocketed by 7581.83% in 2021.
  • Ironwood Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $965625.0 in 2020, then soared by 75.82% to $1.7 million in 2021, then fell by 21.8% to $1.3 million in 2022, then grew by 25.34% to $1.7 million in 2023, then rose by 13.36% to $1.9 million in 2024.
  • Its Gains from Sales and Divestitures stands at $1.9 million for Q4 2024, versus $1.7 million for Q4 2023 and $1.3 million for Q4 2022.